Update on Phase 3 GY004 of cediranib and olaparib in platinum-sensitive relapsed ovarian cancer

The trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in progression-free survival with cediranib, an investigational oral VEGFR inhibitor, in combination with olaparib vs. platinum-based chemotherapy.


Biospace Inc.